Sernova Corp.

Equities

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

End-of-day quote Toronto S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
0.32 ^CAD	-1.54%		-13.51%	-54.29%

25/04	Sernova Corp. Announces Board and Management Changes	CI
25/04	Sernova Corp. Announces Workforce Reduction	CI

Sernova Corp. Announces Board and Management Changes

April 26, 2024 at 01:46 am IST

Sernova Corp. announced the retirement of Chief Technology Officer (CTO), Dr. Philip Toleikis effective April 30, 2024. Sernova Director Mr. Bertram von Plettenberg has retired from the company's Board, effective April 23, 2024.

Latest news about Sernova Corp.

Sernova Corp. Announces Board and Management Changes	26/04	CI
Sernova Corp. Announces Workforce Reduction	26/04	CI
Sernova Corp. Provides Positive Clinical and Platform Portfolio Update	02/04	CI
Sernova Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	19/03	CI
Sernova Corp. Announces CFO Changes	11/03	CI
Sernova Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	29/01	CI
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA	27/11	MT
Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System? at the 2023 IPITA-IXA-CTRMS Joint Congress	30/23/30	CI
Sernova Announces Positive Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial	27/23/27	MT
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System? for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress	27/23/27	CI
Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting	29/23/29	CI
Sernova Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	13/23/13	CI
Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device	07/23/07	CI
Sernova Names New CEO, Former CEO Assumes Tech Chief Role	05/23/05	MT
Sernova Corp. Announces Executive Changes	05/23/05	CI
Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer	05/23/05	CI
Sernova Corp Appoints Modestus Obochi as Chief Business Officer	26/23/26	CI
Sernova Corp. Reports Updated Interim Phase 1/2 Clinical Data for Cell Pouch System at American Diabetes Association Meet	26/23/26	MT
Sernova Corp. Brief: Announcing "Positive" Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System at American Diabetes Association 83rd Scientific Sessions	26/23/26	MT
Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch Systemâ„¢? at American Diabetes Association 83rd Scientific Sessions	26/23/26	CI
Sernova Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	14/23/14	CI
Sernova Corp. Announces Executive Changes	31/23/31	CI
ADRs End Mostly Lower; Sernova Gains on AstraZeneca Collaboration	04/23/04	DJ
Toronto Stocks Flat After Tuesday's Decline; Loblaw Shares Slide as 1Q Profit Falls, Revenue Misses	03/23/03	DJ
Sernova Shares Jump With AstraZeneca Collaboration	03/23/03	DJ

Chart Sernova Corp.

Duration

Period

More charts

Company Profile

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.

Sector

Medical Equipment, Supplies & Distribution

Calendar

26/06/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.32 CAD

Average target price

3.02 CAD

Spread / Average Target

+843.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
SERNOVA CORP.	-54.29%	71.36M
SMITH & NEPHEW PLC	-5.10%	11.34B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+4.02%	9.11B
GLAUKOS CORPORATION	+38.12%	5.53B
INSPIRE MEDICAL SYSTEMS, INC.	-23.70%	4.61B
AXONICS, INC.	+8.55%	3.45B
ENOVIS CORPORATION	-6.44%	2.87B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-5.85%	2.1B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-11.84%	2.08B
DOUBLE MEDICAL TECHNOLOGY INC.	-23.36%	1.78B

Medical Devices & Implants